China Resources Pharmaceutical (03320.HK) announced that its subsidiary Runsheng Pharmaceutical has received approval from the U.S. Food and Drug Administration (FDA) for the market launch of salmeterol/fluticasone inhalation powder, marking the first time the FDA has approved an inhalation powder developed independently by a Chinese pharmaceutical company.
The salmeterol/fluticasone inhalation powder is used in a combination therapy (bronchodilator and inhaled corticosteroid) for the regular treatment of reversible obstructive airway diseases, including asthma in adults and children

03320

CHINARES PHARMA announced that its subsidiary Runsheng Pharmaceutical's salmeterol/fluticasone inhalation powder has received marketing approval from the U.S. Food and Drug Administration (FDA), marking the first time the FDA has approved an inhalation powder developed independently by a Chinese pharmaceutical company. The salmeterol/fluticasone inhalation powder is used in a combination therapy (bronchodilator and inhaled corticosteroid) for the regular treatment of reversible obstructive airway diseases, including asthma in adults and children

CHINARES PHARMA's asthma inhalation powder has been approved by the FDA for market launch